Optiray 350: Main Uses and Benefits

Optiray 350 is a radiopaque contrast agent used to enhance visualization during various diagnostic imaging procedures. It is administered by a healthcare professional directly into a vein or artery.

In adults, the uses of Optiray 350 include:

• Angiography: Visualization of blood vessels, specifically for peripheral arteriography, coronary arteriography, and left ventriculography.
• Computed Tomography (CT) Imaging: Enhancement for CT imaging of the head and body.
• Excretory Urography and Venography.
• Intravenous Digital Subtraction Angiography (IV-DSA).

In pediatric patients, Optiray 350 is indicated for angiocardiography to visualize the chambers of the heart and major blood vessels. The benefit of using this agent is to augment the radiographic efficiency of the procedure, allowing for clearer diagnostic assessment of conditions affecting these vascular and organ systems.

---

Quick Facts: Therapeutic Indications

• Assists in diagnostic imaging of the heart and blood vessels (angiography, left ventriculography).
• Enhances visualization during computed tomography (CT) scans of the head and body.
• Used for intravenous excretory urography and venography.

Optiray 350 (ioversol injection) is a radiopaque contrast agent, and its use is subject to specific regulatory eligibility criteria to ensure patient safety.

Contraindications

Use is prohibited for individuals with:

• Hypersensitivity or severe allergic reaction to ioversol, iodine-containing contrast media, or any of the product's excipients.
• Symptomatic (manifest) hyperthyroidism (overactive thyroid gland).

Restricted or Special Caution Populations

The medicine requires special consideration and caution in patients with:

• Severely impaired renal function or combined renal and hepatic disease, due to the risk of acute kidney injury.
• Diabetes mellitus, multiple myeloma, or other paraproteinemia.
• Pheochromocytoma (risk of hypertensive crisis) or homozygous sickle cell disease (risk of sickling crisis).
• A history of asthma or other allergies.
• Cardiovascular conditions such as congestive heart failure or advanced atherosclerosis.

Age and Route Restrictions

• Pediatric Use: Safety and effectiveness are not established in children younger than one month of age. In older children, the drug is primarily indicated for angiocardiography. Caution is advised for all pediatric patients under 18 years, as efficacy is not established for all adult indications.
• Intrathecal Administration: The drug must not be administered by the intrathecal route (into the spinal canal), as this is associated with the risk of severe neurological complications and death.

Interaction Map: Interactions with other medicines and products — official regulatory information for Optiray 350

---

Interaction scope

Category	Details (Strictly from Regulatory Documents)
Medicinal product categories with documented interactions	Nephrotoxic agents, Biguanides (Metformin), Immunomodulators (Aldesleukin), Vasopressors, Radioactive Tracers.
Specific interacting medicines (if explicitly listed)	Amphotericin B deoxycholate, Cidofovir, Neomycin PO (Oral), Metformin, Aldesleukin, Iobenguane I-123/I-131.
Mechanistic basis of interactions (only if stated in label)	Decreased renal clearance of co-administered drug, Additive toxicological effect (e.g., nephrotoxicity), Pharmacodynamic potentiation. Ioversol is minimally metabolized, ruling out common enzyme-mediated interactions.
Timing-based interaction rules (if applicable)	Interference with Radioactive Iodine uptake is documented to last for 6–8 weeks. The Protein-Bound Iodine (PBI) test should not be performed for a minimum of 16 days after administration.
Population-specific interaction notes (if applicable)	The risk of Metformin-associated lactic acidosis is a primary concern, a risk highly dependent on the patient's renal status following contrast administration.
Interaction-related restrictions	The product must not be mixed with other drugs, solutions, or total parenteral nutrition mixtures. Arterial injection should not follow the administration of Vasopressors due to potentiation of neurologic effects.

---

Interaction classifications (high-level)

Classification	Details (Strictly from Regulatory Documents)
Interaction severity classification (as defined in official documents)	Contains formally Contraindicated Combinations (e.g., Amphotericin B deoxycholate), as well as interactions requiring timing separation or dosage modification (e.g., Metformin).
Regulatory basis (EMA / FDA / etc.)	Information is based on government-published prescribing information (FDA DailyMed, EMA Summary of Product Characteristics).
Interaction-context constraints (as defined in official documents)	The interaction risk with Metformin is contingent on acute renal dysfunction post-contrast. The effect on Radioactive Iodine uptake is a temporary reduction in diagnostic and therapeutic efficacy.

---

Resulting interaction structure

Official interaction statements:

• Contraindicated combinations include Amphotericin B deoxycholate, Cidofovir, and Neomycin PO due to compounded risk of nephrotoxicity.
• Ioversol decreases the renal clearance of Iobenguane I-123/I-131, resulting in increased plasma concentrations of Iobenguane.
• Co-administration with Metformin carries a risk of lactic acidosis secondary to renal dysfunction that may follow contrast administration.
• Aldesleukin may enhance the potential for allergic or hypersensitivity reactions to the contrast agent.
• The Protein-Bound Iodine (PBI) test should not be performed for a minimum of 16 days following administration.
• The product must not be mixed with other medicinal products.

Connection to the overall interaction profile (2–4 sentences):

Regulatory documents define the product's interaction structure primarily through two domains: additive toxicological effects on the kidneys and interference with iodine-dependent diagnostic or therapeutic procedures. The profile emphasizes interactions related to renal clearance modification and pharmacodynamic potentiation, given that Ioversol is largely excreted unchanged and does not undergo significant hepatic metabolism. Mandatory timing requirements are established specifically for diagnostic tests and treatments that rely on iodine uptake.

How Optiray 350 Works: Mechanism of Action

Optiray 350 (ioversol) functions not through biological modulation, but by physical attenuation principles. The molecule delivers a high concentration of iodine atoms, an electron-dense element, into the body's fluid compartments. The mechanism relies on this high atomic mass component to efficiently absorb or block X-ray photons, thereby creating areas of high radiopacity on diagnostic images.

The drug's action is governed by its pharmacokinetics. Following administration, its highly water-soluble nature facilitates passive distribution primarily throughout the intravascular and extracellular fluid spaces, where the contrast effect is initiated. This temporary concentration of the agent delineates the structure and flow of the vascular network and adjacent soft tissues.

Termination of the contrast effect is achieved solely through renal clearance. The unmetabolized molecule is rapidly filtered from the plasma by the glomeruli and excreted into the urinary tract. This swift elimination process ensures the physical radiodensity effect is transient, dictating the short duration of the system-level physiological change.

Administration Guidelines

Optiray 350 (ioversol injection) is a diagnostic radiopaque agent for intravascular use only; it must not be administered intrathecally (into the spinal canal), as this is associated with severe adverse events, including death. The solution is intended for injection or infusion into a vein (intravenous) or an artery (intra-arterial).

Preparation and Procedural Steps

Prior to administration, the solution should be inspected for particulate matter or discoloration and must be discarded if either is observed. It is recommended that the solution be warmed to body temperature before injection. The administration must be performed using sterile technique, and patients should be well-hydrated before and after the procedure to help minimize potential risks. Unused portions of the product must be discarded.

Dosing Instructions

The dosage of Optiray 350 is determined by the healthcare provider and is based on the specific procedure, the patient's age, weight, and general health condition. The lowest dose necessary to achieve adequate visualization should be used.

For adults undergoing multiple angiographic procedures, the maximum cumulative dose typically should not exceed 250 mL. For intravenous procedures like Computed Tomography (CT) imaging of the head and body, the dose generally ranges from 50 mL to 150 mL via infusion, or a combination of bolus injection (25 mL to 75 mL) and infusion, depending on the imaging target.

Administration Route	Example Adult Dose (Optiray 350)	Maximum Cumulative Dose
Left Coronary Artery	8 mL (range 2–10 mL)	250 mL
Left Ventricle	40 mL (range 30–50 mL)	250 mL
CT Body Imaging (Infusion)	50 mL to 150 mL	Not explicitly limited by cumulative dose for IV procedures

In pediatric patients, Optiray 350 is specifically indicated for angiocardiography, but its safety and efficacy in children for other procedures have not been fully established and use is evaluated on an individual basis.

Research Evidence / Overview of Studies for Optiray 350

Evidence for Visualization of Blood Vessels (Angiography)

The evidence base for Optiray 350's use in visualizing blood vessels, such as for peripheral arteriography and coronary arteriography, includes randomized controlled trials (RCTs) and comparative studies. These studies were applied in research contexts involving adults referred for diagnostic procedures. This involved assessing the quality of the diagnostic image obtained and monitoring acute changes in physiological measures (such as heart rate and blood pressure) immediately following administration.

Comparative trials examined the procedural tolerance of the agent, with studies focusing on patient-reported outcomes describing perceived discomfort (such as heat or pain sensation) when used alongside high-osmolar alternatives.

Evidence for Diagnostic CT Imaging

Optiray 350 was studied for use in enhancing computed tomography (CT) scans of both the head and body through a combination of clinical trials and pharmacokinetic (PK) studies. The research examined temporary physiological imbalance related to how the agent moved through the body. Specifically, studies monitored the degree and duration of contrast enhancement in tissues and measured the systemic clearance profile, which describes how quickly the iodine is eliminated, primarily through the kidneys.

Research describes the contrast temporarily achieving visualization for diagnostic purposes in the observed populations. These studies provide insight into the short-term changes required for the procedure, noting that the agent's clearance from the body largely occurs within 24 hours.

Research in Specific and Vulnerable Populations

Optiray 350 was studied for use in pediatric patients requiring angiocardiography to visualize the chambers of the heart and major blood vessels. The clinical data available for this group was evaluated in studies that examined the diagnostic visualization and the acute procedural effects in children. This evidence contributes to the broader evidence landscape but exists in smaller study sizes compared to the main adult indications.

However, research limitations exist for the very youngest population. Specifically, data for certain groups remain insufficient, as the effectiveness was not established in infants less than one month old at the time of regulatory review. Therefore, results apply only to the populations studied and specific evidence remains limited for groups where data are constrained.

What Remains Uncertain in the Research Base

The primary research limitation frames are that follow-up durations were limited to the acute period, and studies often examined immediate procedural outcomes rather than later clinical outcomes reflecting functional characteristics. Long-term effects are not fully established, and comparative evidence is lacking in certain subgroups and specific procedures.

Key Studies & References OPTIRAY 350- ioversol injection, Full Prescribing Information and Clinical Pharmacology Summary (DailyMed)

Common questions about Optiray 350 (FAQ)

Q: What specific organs or body parts does Optiray 350 help doctors see?

According to official product information, Optiray 350 is indicated for procedures to visualize blood vessels, which include angiography of the coronary arteries, peripheral, visceral, and renal vessels, and the aorta. It is also used in CT scans of the head and body, intravenous urography, and venography. Its function is to temporarily enhance the visualization of these internal structures for diagnostic purposes.

Q: What is the difference between Optiray 350 and Optiray 320?

The number in the name refers to the concentration of the active imaging ingredient, iodine. Optiray 350 has a concentration of 350 milligrams of organically bound iodine per milliliter of solution. Optiray 320 would contain 320 milligrams of iodine per milliliter. This difference in concentration impacts the imaging strength used for various procedures.

Q: What should a patient expect to feel immediately after the injection starts?

Official documents state that the most common feeling reported by patients is a sensation of warmth or flushing throughout the body. Other common sensations include pain at the injection site or nausea. These feelings are typically temporary and short-lived.

Q: How long after receiving Optiray 350 should I wait before having another medical test?

Official product labeling specifies that Optiray 350 is known to interfere with tests that rely on iodine uptake. Specifically, it can interfere with the Protein-Bound Iodine (PBI) test for a minimum of 16 days, and with procedures using Radioactive Iodine for 6–8 weeks. For any other scheduled medical tests, it is important to discuss timing with the healthcare provider.

Q: What does it mean that Optiray 350 is a 'non-ionic' contrast agent?

Optiray 350 is classified as a non-ionic, low osmolar contrast agent. This means the substance does not separate into charged particles (ions) when dissolved, and it has a lower osmotic pressure, or 'thickness,' compared to older contrast agents. This characteristic is recognized to contribute to its overall profile during its administration into a blood vessel.

Q: What ingredients are in Optiray 350 besides the active substance ioversol?

The solution contains the active imaging ingredient ioversol. Inactive ingredients (excipients) are added for stability and proper function. These typically include tromethamine (a buffer), tromethamine hydrochloride, and edetate calcium disodium, along with water for injection. The final acidity (pH) is adjusted using hydrochloric acid or sodium hydroxide.

Q: Why is dehydration a significant concern after receiving Optiray 350?

Official warnings state that preparatory dehydration is discouraged, particularly for at-risk patients. Since the contrast agent is eliminated solely through the kidneys, dehydration may contribute to the risk of Acute Renal Failure (AKI) following the procedure.

Q: Does Optiray 350 contain any known allergens besides iodine?

The product contains the active substance ioversol and excipients such as tromethamine and sodium calcium edetate. Regulatory documents indicate that a hypersensitivity reaction to any of the product's excipients is considered a contraindication for use.

Q: How quickly does the feeling of warmth or flushing usually go away?

While regulatory documents do not specify an exact duration for the feeling of warmth, they state that adverse reactions are generally of short duration and resolve spontaneously without intervention. The product's biological half-life, which is the time it takes for half of the substance to be eliminated, is approximately 1.5 to 2 hours.

Q: Is it normal to feel a metallic or unusual taste after the injection?

Official labeling lists dysgeusia as a possible adverse reaction. This is the clinical term for a distortion or impairment of the sense of taste, which aligns with common user reports of an unusual or metallic taste during or immediately following the injection.

Q: Can allergic reactions to Optiray 350 be delayed?

Yes, regulatory information indicates that most severe reactions occur shortly after injection, but delayed hypersensitivity reactions may occur. Symptoms for these delayed reactions can begin anywhere from a few hours up to several days after the contrast agent is administered.

Q: What is the longest time a delayed reaction to Optiray 350 can occur after the injection?

The product information states that severe cutaneous adverse reactions, which are serious skin conditions, have been reported to develop from 1 hour up to several weeks after intravascular contrast administration.

Q: Is Optiray 350 safe for use during pregnancy?

Official regulatory documents indicate that the safety of Optiray 350 has not been established for use during pregnancy. The product is known to cross the placenta and should only be administered if the diagnostic information gained is considered essential.

Q: What are the recommendations for breastfeeding mothers who receive Optiray 350?

There is no specific information on the presence of the product in human milk. A healthcare provider makes the determination on whether to continue or discontinue breastfeeding/drug use, considering the importance of the drug for the mother's health and the potential effects on the infant.

Q: Is there a higher risk of side effects for elderly patients receiving Optiray 350?

Official warnings advise that caution should be exercised in elderly patients. Older adults are more likely to have underlying age-related issues with their heart, liver, or kidneys. Official documents suggest careful consideration, as advanced age may necessitate specific medical precautions.

Q: What is extravasation and why is it a concern during the injection?

Extravasation is when the contrast medium leaks out of the blood vessel and into the surrounding tissue at the injection site. Regulatory documents note that while this is often tolerated, cases of serious tissue damage have been reported, occasionally requiring surgical treatment.

Q: Can Optiray 350 cause temporary changes in vision or hearing?

Adverse reactions listed in the official product labeling include temporary effects on the sensory organs. These include vision blurred and conditions related to the ears, such as tinnitus (ringing in the ears) or vertigo.

Q: Why do healthcare providers monitor patients for 30 to 60 minutes after the injection?

Monitoring for at least 30 to 60 minutes following administration is advised because severe delayed reactions have been known to occur in the acute post-injection window. This requires emergency facilities and competent personnel to be available.

Q: How does my medical history of prior contrast use affect my risk for Optiray 350?

Official product information states that having a history of a previous reaction to a contrast medium is associated with an increased risk of developing intolerance or hypersensitivity reactions to Optiray 350. A history of a previous reaction is a factor for the medical team to consider.

Q: Can I drive immediately after receiving Optiray 350?

Official documents advise that driving or operating machinery is not advisable for 30 to 60 minutes following administration. This temporary measure is in place due to the risk of early adverse reactions that could impair ability to safely operate vehicles or machinery.

Storage and Disposal of Optiray 350 (Ioversol)

Optiray 350 must be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). It is required to protect the solution from light and to keep it from freezing.

Handling and Stability

Prior to use, the solution must be visually checked; do not use Optiray 350 if it contains particulate matter or shows marked discoloration. For single-dose containers, any unused portion must be discarded immediately after the procedure. The medication must be kept out of the sight and reach of children.

Disposal

Unused, expired, or residual Optiray 350 must be disposed of in accordance with all applicable local and federal regulations for pharmaceutical waste.